Celltrion Deal History & Licensing Activity
Celltrion is a large biotech headquartered in South Korea. Over the past three years, Celltrion has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (3 deals). The company currently has 22 active clinical trials, primarily in Autoimmune.
Deals (12mo)
1
Active Trials
22
Top Modality
Antibodies
Focus Area
Autoimmune
Celltrion Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Celltrion in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| TROCAD antibody platform | TriOar | Antibodies | Unknown | option | May 2026 |
Celltrion Pipeline Focus
Therapeutic areas and modalities where Celltrion is most active based on deal history and clinical trial data.
Therapeutic Areas
Celltrion Strategic Signals
Key indicators of Celltrion's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Celltrion Clinical Pipeline
Celltrion has 22 active clinical trials across 6 development phases.
4
Unknown
2
Not Applicable
2
Phase 4
3
Phase 1
2
Phase 2
9
Phase 3
See How Your Asset Matches Celltrion's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Celltrion Licensing & Deal Activity
Celltrion is a large biotech company based in South Korea that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Celltrion ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Celltrion include Autoimmune (8 deals and trials), Metabolic (5 deals and trials), Option Deals (3 deals and trials), and Hematological Malignancies (2 deals and trials). In terms of modality, Celltrion has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Celltrion and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Celltrion's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.